Analytical Data
-
Gene name
NF1
- Application
-
Alternative Names
(Neurofibromatosis-related protein NF-1)
-
Species
Human
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P21359
-
Expression Region
1566-1837aa
-
Molecular Weight
38.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Neurofibromatosis type 1 (NF1) is a genetic disorder caused by mutations in the NF1 gene, which encodes the neurofibromin protein, a key regulator of the RAS signaling pathway. Neurofibromin functions as a tumor suppressor, as it negatively regulates RAS activity, thus playing a crucial role in cell growth and differentiation. Patients with NF1 commonly present with benign tumors known as neurofibromas, as well as an increased risk of malignant tumors and various neurological issues. The study of NF1 recombinant protein is critical for understanding the molecular mechanisms underlying NF1 and the biological functions of neurofibromin. By expressing and purifying NF1 recombinant protein, researchers aim to investigate its structure, function, and interactions with other cellular proteins, which can provide insights into the development of targeted therapies. This research not only enhances our understanding of NF1 pathophysiology but also aids in the identification of potential biomarkers for early diagnosis and prognosis. Furthermore, the characterization of NF1 recombinant protein may facilitate drug discovery efforts, leading to innovative treatments that specifically address the complications associated with NF1, ultimately improving patient outcomes and quality of life.
